PU
PURE Bioscience, Inc.
PURE · OTC
$0.07 -17.79% (-$0.01)
1M +29.97%
Market Cap $10.4M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.1
52.4% upside
Current Price
$0.066
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PURE is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
3 /100
Expensive EV/EBITDA 85.89x
P/S 4.28x
P/E N/A
Growth
65 /100
Stable Rev. growth 5.92%
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Gross margin 53,803.60%
FCF margin 73.49%
Net margin 91.04%
Quality
21 /100
Poor ROIC 291.19%
Asset turnover 1.55x
ROA 141.53%
Debt
0 /100
High Current ratio 0.42x
Net debt/EBITDA 29.81x
Int. coverage -0.01x
Stability
62 /100
Moderate Beta 0.23x
Profitable years 0
Rev. volatility 5.58%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PURE
Online
Sector
Basic Materials
Industry
Chemicals
CEO
Jeff Kitchell
Employees
12
Headquarters
El Cajon